Janati A Bruce, Alghasab Naif, Osman Aboubaker
Center For Neurology, Fairfax, VA 22031, USA.
Case Rep Neurol Med. 2012;2012:183252. doi: 10.1155/2012/183252. Epub 2012 Jul 24.
A 32-year-old female, with a history of secondarily-generalized convulsive epilepsy, mental retardation, and a psychiatric illness, developed neuroleptic malignant syndrome while receiving carbamazepine and amitriptyline concurrently. We hypothesize that the addition of amitriptyline to carbamazepine caused a decrease in the serum level of carbamazepine, resulting in NMS. We conclude that combination therapy with carbamazepine and amitriptyline should be avoided in patients who are predisposed to NMS. The purpose of this paper is to warn physicians against combination therapy with carbamazepine and tricyclic antidepressants which may be conducive to neuroleptic malignant syndrome in susceptible patients.
一名32岁女性，有继发性全身性惊厥性癫痫、智力发育迟缓及精神疾病史，在同时服用卡马西平和阿米替林时发生了抗精神病药恶性综合征。我们推测，在卡马西平基础上加用阿米替林导致卡马西平血清水平降低，从而引发了抗精神病药恶性综合征。我们得出结论，对于易发生抗精神病药恶性综合征的患者，应避免卡马西平和阿米替林联合治疗。本文旨在提醒医生，卡马西平和三环类抗抑郁药联合治疗可能会使易感患者发生抗精神病药恶性综合征。
